Drug Profile
DUP 856
Latest Information Update: 21 Jan 1997
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antidementias; Neuroprotectants
- Mechanism of Action Neurotransmitter stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 14 Jun 1996 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)